Clinical Trials Logo

Effect of Drugs clinical trials

View clinical trials related to Effect of Drugs.

Filter by:

NCT ID: NCT05311540 Completed - Preterm Infant Clinical Trials

Zinc Supplementation In Very Low Birth Weight Infants-A Randomised Controlled Trial

Start date: March 14, 2014
Phase: Phase 4
Study type: Interventional

- Zinc (Zn) is a structural component of human body and is a crucial element for a wide variety of cascades that take place in almost all organ systems. - Due to many reasons, preterm infants are generally believed to be naturally in a negative Zn balance during the early periods of life. - Regulation of intestinal Zn absorption of preterms is unrelated to infant's Zn status. - There still is a lack of knowledge in the possible relation of Zn deficiency and development of NEC and/or feeding intolerance in preterm infants. - Even if Zn is studied as an adjunct treatment for neonates and young infants with sepsis and found to reduce treatment failure in these high risk population, data in preventing infectious diseases in preterm infants is still lacking.

NCT ID: NCT04554589 Not yet recruiting - Effect of Drugs Clinical Trials

The Off Label Use of Glycopyrrolate in the Adults Intensive Care Unit.

Start date: September 14, 2020
Phase: Phase 1
Study type: Interventional

Tracheostomized patients in the ICU can have excessive tracheal secretions due to various causes as hyperactive airway, irritation of the mucus producing cells and inhibition of the ciliary functions. Excessive secretions will necessitate frequent suctions which carries the risk of tracheostomy tube obstruction if not managed properly. Excessive tracheal secretions may prolong the ICU stay, increase the nurses workload and increase patients morbidity and mortality. This clinical trial hypothesizes that the use of glycopyrrolate may decrease the tracheal secretions and hence avoid such complications.

NCT ID: NCT04338802 Not yet recruiting - COVID-19 Clinical Trials

Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19

Start date: April 2, 2020
Phase: Phase 2
Study type: Interventional

This center intends to conduct a single-center, randomized, placebo-controlled study to evaluate the effectiveness and safety of Nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe COVID-19.

NCT ID: NCT04326504 Recruiting - HIV Infections Clinical Trials

Dolutegravir and Clinical Outcomes Among ART-recipients in Brazil

CODE
Start date: February 1, 2021
Phase:
Study type: Observational [Patient Registry]

Access to antiretroviral therapy (ART) in low-income and middle-income countries has been scaled-up effectively over recent years. Recently, the World Health Organization (WHO) guidelines changed to recommend the use of Dolutegravir (DTG) combined with two nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir and lamivudine, for first-line ART; however, there is still a need for further data on the outcomes of DTG-based regimens for people with HIV-1. This study aims to describe the outcomes of drug-naïve and experienced patients starting a dolutegravir (DTG)-based regimen in a large cohort of HIV - infected patients in Brazil and compare to outcomes obtained from a retrospective control group of subjects who initiated non-DTG-based ART.

NCT ID: NCT04296838 Terminated - Macular Edema Clinical Trials

Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF

Start date: October 12, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

As a primary exploratory study, this study aims to evaluate the short-term effectiveness of intravitreal Conbercept injection in UME, and to explore the correlation between inflammatory factors like VEGF and the responsiveness to treatment.

NCT ID: NCT04170088 Completed - Effect of Drugs Clinical Trials

Comparison of Efficacy of Tranexamic Acid Mesotherapy Versus 0.9% Normal Saline for Melasma

Start date: September 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

It is a randomized controlled trial in which investigators determine the efficacy of tranexamic acid (TA) by mesotherapy in comparison to normal saline on participants having Melasma.

NCT ID: NCT04110808 Not yet recruiting - Effect of Drugs Clinical Trials

Comparative Effect of Hypotensive Anaesthesia on Event Related Potentials, Quantitative Electroencephalograghy

Start date: October 15, 2019
Phase: Early Phase 1
Study type: Interventional

AIM OF THE WORK The aim of this work was to compare the effect of hypotensive anaesthesia using Nitroglycerine versus phentolamine on Event related potentials, quantitative Electroencephalograghy and cognitive function, in patients undergoing septoplasty.

NCT ID: NCT04044378 Withdrawn - Pediatric Cancer Clinical Trials

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Start date: August 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Results of previous study showed high objective response but short-term activity of anti-angiogenesis tyrosine kinase inhibitors in advanced osteosarcoma. Given the recent success of immunotherapies, combinations of antiangiogenics with immune checkpoint blockers have become an attractive strategy. The investigators had completed an prospective phase 2 trial of the combination of apatinib and camrelizumab on advanced osteosarcoma and showed prolonged progression-free survival for this combination. Famitinib is a novel tyrosine kinase inhibitor targeting VEGFR-2, -3 and FGFR-1, -2, -3, -4 with high affinity, which showed broad antitumor activity against a variety of xenograft models. A Study to Compare the Efficacy and Safety of Levatinib with or without Ifosfamide and Etoposide in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma showed promising median PFS of 11.3 months. Thus we also try to investigate the combination efficacy of TKIs with chemotherapy in advanced osteosarcoma. This study aims to investigate the recommended phase 2 dose for pediatric use of famitinib in combination with camrelizumab and trys to explore the efficacy and safety for single drug famitinib, famitinib and camrelizumab and famitinib and ifosfamide in patients with inoperable high-grade osteosarcoma progressing after chemotherapy.

NCT ID: NCT04042597 Recruiting - Quality of Life Clinical Trials

Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma

CSSG-03
Start date: July 18, 2019
Phase: Phase 2
Study type: Interventional

For local relapse not amenable to reasonable curative surgery or for those with metastatic chordoma, chemotherapy is recognised as inactive. The major study drug is the small molecular tyrosine kinase inhibitors targeted at the stem cell factor receptor (KIT) and the platelet-derived growth factor receptors (PDGFRA and PDGFRB), eg. imatinib. Anlotinib is a novel tyrosine kinase inhibitor targeting both at VEGFR-2, -3 and PDGFRA and PDGFRB with high affinity, which also showed broad antitumor activity against EGFR and so on. Thus this multicenter, two-armed phase II trial of PKUPH-sarcoma 05 intended to investigate the efficacy and safety of anlotinib versus imatinib on advanced chordoma.

NCT ID: NCT04027543 Completed - Safety Issues Clinical Trials

Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma(NewEC Study)

Start date: November 14, 2018
Phase:
Study type: Observational

To provide comprehensive efficacy and safety profiles of neoadjuvant chemoradiotherapy (NCRT) versus neoadjuvant chemotherapy (NCT) versus surgery alone in resectable oesophageal carcinoma.